Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Recruiting 6Completed 4Active not recruiting 3

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 4Prostatic Neoplasms, Castration-Resistant 1Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

Specimen Handling 311Magnetic Resonance Spectroscopy 266pembrolizumab 251Carboplatin 184Cyclophosphamide 176Biopsy 172Cisplatin 157Gemcitabine 134Paclitaxel 131Bevacizumab 124fludarabine 117Radiotherapy 108Nivolumab 108Oxaliplatin 88Docetaxel 87Fluorouracil 85Capecitabine 83venetoclax 82Dexamethasone 77Pemetrexed 72Rituximab 71Leucovorin 69Drug Therapy 69atezolizumab 67durvalumab 66Radiosurgery 65Blood Specimen Collection 65Standard of Care 63Doxorubicin 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × cabazitaxel × 90 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07213674 2026-06-04

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Amgen

Phase 3 Recruiting
750 enrolled
Genitourinary

Prostatic Neoplasms

NCT06632977 2026-06-02

PREDICT

Alliance for Clinical Trials in Oncology

Phase 2 Recruiting
474 enrolled
Genitourinary

Prostatic Neoplasms

NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06085729 2026-04-02

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡